梦华于2019年6月在暨南大学获得学士学位，2019年9月进入中山大学药学院(深圳)高理钱老师课题组开始研究生期间的学习，现为中山大学2019级在读硕博连读研究生。

E-mail: xiangmh5@mail2.sysu.edu.cn

Publications (After joining SYSU) （# Equal contribution, * Corresponding author）

1. B. Sharma#, L. Xie#, F. Yang#, W. Wang#, Q. Zhou, M. Xiang, S. Zhou, W. Lv, Y. Jia, L. Pokhrel, J. Shen, Q. Xiao*, L. Gao*, W. Deng*, “Recent advance on PTP1B inhibitors and their biomedical applications”, European Journal of Medicinal Chemistry (2020),  199:112376, doi:10.1016/j.ejmech.2020.112376.

2. M. Xiang#, Q. Zhou#, Z. Shi, X. Wang, M. Li, Y. Jia, S. Li, F. Yang, W. Wang, B. Sharma, Y. Nie, Q. Xiao*, L. Gao*, “A review of light sources and enhanced targeting for photodynamic therapy”, Current Medicinal Chemistry (2021), 28(31), 6437-6457.

3. Q. Xiao, B. Mai, Y. Nie, C. Yuan, M. Xiang, Z. Shi, J. Wu, W.A. Leung, C.S. Xu*, S.Q. Yao*, P. Wang*, L. Gao*, “In Vitro and In Vivo Demonstration of Ultra-Efficient and Broad-Spectrum Antibacterial Agents for Photodynamic Antibacterial Chemotherapy”, ACS Applied Materials & Interfaces (2021), 13(10):11588-11596.

4. W.J. Shi*, L., Feng, X. Wang, Y. Huang, Y.F. Wei, Y.Y. Huang, H.J. Ma, W. Wang, M. Xiang, L. Gao*, “A near-infrared-emission aza-BODIPY-based fluorescent probe for fast, selective, and “turn-on” detection of HClO/ClO^-”, Talanta (2021),  233,122581.

5. Q. Xiao*, X. Dong, F. Yang, S. Zhou, M. Xiang, L. Lou, S.Q. Yao*，L. Gao*, “Engineered Cell-penetrating Peptides for Mitochondrion-Targeted Drug Delivery in Cancer Therapy”, Chem. Eur. J. (2021), 27(59), 14721-14729. 

6. P. Chen#, J. Sun#, C. Zhu#, G. Tang*, W. Wang, M. Xu, M. Xiang, C.-J. Zhang, Z.-M. Zhang*, L. Gao*, S. Q. Yao*, “Cell-active, reversible and irreversible covalent inhibitors that selectively target the catalytic lysine of BCR-ABL kinase”, Angew. Chem. Int. Ed. (2022), 61(26):e202203878.

7. C. Yuan#, K. Ai#, M. Xiang, C. Xie, M. Zhao, M. Wu, H. Li, Y. Wu, Y. Cao, C. Li, X. Pei, Y. Zhong, H. K.W. Law, L. Gao, Q. Xiao*, X. Yang*, “Novel 1-hydroxy phenothiazinium-based derivative protects against bacterial sepsis by inhibiting AAK1-mediated LPS internalization and caspase-11 signaling”, Cell Death & Disease (2022), 13(8):722.

8.P. Chen#, G. Tang#, *, C. Zhu#, J. Sun, X. Wang, M. Xiang, H. Huang, W. Wang, L. Li, Z. Zhang*, L. Gao*, S.Q. Yao*, “ 2-Ethynylbenzaldehyde (EBA)-based, lysine-targeting irreversible covalent inhibitors for protein kinases and non-kinases”, J. Am Chem. Soc. (2023),145 (7)，3844-3849, 中科院1区，Top Journal). 

9. W. Wang#, X. Wang#, G. Tang*, C-J Zhu, M. Xiang, Q. Xiao, Z.-M. Zhang*, L. Gao*, S.Q. Yao*, “Dual inhibitors/probes that target LRRK2 and AURORA A kinases noncovalently and covalently”, Chem. Commun.(2023), in press, DOI:10.1039/D3CC03530A. 

10.P. Chen#, J. Sun#, L. Wang#, M. Xiang, M. Gu, F. Miao, X. Wang, L. Duan, P. Yuan, Z.-M. Zhang*, X. Lu*, L. Gao*, S.Q. Yao*, “Cell-Active, Arginine-Targeting Irreversible Covalent Inhibitors for Protein Kinases and Non-Kinases”, XXXX (2023), submitted.

11.X. Wang, J. Sun, H. Huang, G. Tang, P. Chen, M. Xiang, L. Li, Z.-M. Zhang,* L. Gao,* S.Q. Yao*, “Kinase Inhibition via Small Molecule-Induced Intramolecular Protein Cross-Linking”, Angew Chem Int Ed (2024), e202404195. 

12. M. Xiang#, F. Yang#, P. Chen, J. Chen, J. Zhang, J. Yang, Y. Liu, Q. Zhang, J. Pi*, P. Yuan*, S.Q. Yao*, and L. Gao*, “Tumor Microenvironment-Responsive Self-Assembled Nanomedicine for Reversible Covalent Targeting of BCR-ABL Kinase”, XXXX (2024), submitted.

Patents

1.肖奇才，高理钱，周全明，石子寒，汪伟，向梦华，谢刘幸，杨芬，罗川朝。“一种氟替卡松丙酸酯中间体的制备方法”。中国发明专利申请号：CN202010150457.6,申请日2020年03月06日

2. 肖奇才，尹国建，高理钱，向梦华。“一种激光器”。中国发明专利申请号：CN202010151860.0, 申请日2020年03月06日

3. 肖奇才，尹国建，高理钱，向梦华。“一种激光器”。中国实用新型专利申请号：CN202020273439.2, 申请日2020年03月06日,授权公告日：2020年10月9日，专利号ZL202020273439.2, 授权公告号CN211655311U

4. 高理钱,顾明希,孙杰,周士哲,陈鹏,向梦华，“一种靶向Bcr-Abl 的分子胶及其制备方法和用途”， 中国发明专利申请号2024113845620，申请日2024 年09 月30 日